Article Text

Download PDFPDF
Review
Neuroendocrine tumours found at endoscopy: diagnosis and staging
  1. Mohid S Khan1,
  2. Raj Srirajaskanthan2,3,
  3. Aviva Frydman2,
  4. D Mark Pritchard4,5
  1. 1South Wales NET Service, Department of Gastroenterology, Cardiff and Vale University Health Board, Cardiff, UK
  2. 2Neuroendocrine Tumour Unit, King's College Hospital, London, UK
  3. 3Department of Gastroenterology, King's College Hospital, London, UK
  4. 4Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
  5. 5Liverpool ENETS Centre of Excellence, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
  1. Correspondence to Professor D Mark Pritchard; mark.pritchard{at}liverpool.ac.uk

Abstract

Due to their increasing incidence, neuroendocrine neoplasms (NENs) are being detected more frequently by endoscopists while they are performing diagnostic upper or lower gastrointestinal (GI) endoscopies. These procedures are usually performed for unrelated indications or for screening, with the tumours often being detected incidentally. The most common scenario is of an endoscopist being surprised by receiving a histology report of a well-differentiated neuroendocrine tumour (NET) after biopsying a small polyp that was initially thought to be benign. This article aims to provide some guidance about what to do next in that situation. All patients with NET should, however, be referred to a fully constituted NEN multidisciplinary team for definitive investigations and management.

In general, the site, size and number of any possible NENs should be fully assessed during the initial endoscopy and representative endoscopic images should be captured. If the initial endoscopic assessment was inadequate, the procedure may need to be repeated. Possible NENs should be sampled using biopsy forceps. Endoscopic resection should only be attempted following histological confirmation of the diagnosis and tumour grade and after additional investigations have been performed to fully stage the tumour and determine its hormone production status. This is essential so that patients do not undergo either unnecessary or inadequate endoscopic resections.

This article discusses the endoscopic features and subsequent assessment of NENs that arise in the stomach, duodenum, terminal ileum and rectum, as these are the common tumour sites within the GI tract.

  • GASTROSCOPY
  • COLONOSCOPY

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • X @gastrolivuni

  • MSK and RS contributed equally.

  • Contributors MSK, RS, AF and DMP wrote sections of the first draft of this review and all authors revised the final article. DMP is the corresponding author.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MSK has received consultancy funding/speaker fees from Ipsen, Novartis and Esteve. RS has received consultancy funding/speaker fees and research grants from Ipsen, Novartis and ITM. DMP has received consultancy funding/speaker fees from Ipsen, Novartis and OranoMed and research funding to investigate gastric NETs from Trio Medicines Ltd.

  • Provenance and peer review Commissioned; externally peer reviewed.